TXG - 10x Genomics reports mixed Q1 earnings; raises FY23 outlook
2023-05-03 16:41:09 ET
- 10x Genomics press release ( NASDAQ: TXG ): Q1 GAAP EPS of -$0.44 misses by $0.06 .
- Revenue of $134.3M (+17.3% Y/Y) beats by $5.43M .
- Gross margin was 73% for the first quarter of 2023, as compared to 78% for the corresponding prior year period.
- Cash and cash equivalents and marketable securities were $418.3 million as of March 31, 2023.
- FY23 guidance : 10x Genomics is raising its full year 2023 revenue guidance and now expects revenue in the range of $590 million to $610 million vs. consensus of $593.21M, representing 14% to 18% growth over full year 2022. This compares to its previous revenue guidance of $580 million to $600 million.
For further details see:
10x Genomics reports mixed Q1 earnings; raises FY23 outlook